Biomarker‐adapted treatment in high‐risk large B‐cell lymphoma

Abstract Survival rates for patients with high‐risk large B‐cell lymphoma (LBCL), particularly those with biological risk factors, remain inadequate. We conducted a biomarker‐driven phase II trial involving 123 high‐risk patients aged 18–64 with LBCL. Based on their biological risk profiles, patient...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Sirpa Leppä, Leo Meriranta, Maare Arffman, Judit Jørgensen, Marja‐Liisa Karjalainen‐Lindsberg, Klaus Beiske, Mette Pedersen, Kristina Drott, Annika Pasanen, Kristiina Karihtala, Susanna Mannisto, Bente Wold, Marianne Brodtkorb, Unn‐Merete Fagerli, Thomas Stauffer Larsen, Lars Munksgaard, Kaisa Sunela, Øystein Fluge, Sirkku Jyrkkiö, Peter Brown, Harald Holte
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2025-05-01
Serie:	HemaSphere
Accesso online:	https://doi.org/10.1002/hem3.70139
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Biomarker‐adapted treatment in high‐risk large B‐cell lymphoma

Documenti analoghi